Premium
Role of positron emission tomography imaging in Multiple Endocrine Neoplasia syndromes
Author(s) -
July Mose,
Santhanam Prasanna,
Giovanella Luca,
Treglia Giorgio
Publication year - 2018
Publication title -
clinical physiology and functional imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.608
H-Index - 67
eISSN - 1475-097X
pISSN - 1475-0961
DOI - 10.1111/cpf.12391
Subject(s) - medicine , positron emission tomography , somatostatin receptor , endocrine system , neuroendocrine tumors , pet imaging , scintigraphy , functional imaging , nuclear medicine , radiology , somatostatin , hormone
Summary The aim of this review was to summarize the recent developments on the role of positron emission tomography ( PET ) imaging using different radiopharmaceuticals in patients with multiple endocrine neoplasia ( MEN ) syndromes. Although most guidelines do not mention the use of PET imaging in patients with MEN syndromes, recent data seem to suggest a relevant diagnostic role of PET imaging in this setting. In particular, latest evidence has shown that somatostatin receptor PET provides a diagnostic accuracy in detecting MEN syndromes‐related neuroendocrine tumours ( NET s) higher than that of somatostatin receptor scintigraphy, thus influencing patient management in a significant percentage of cases. 18 F‐ DOPA PET seems to have a potential role in detecting MEN ‐2‐related NET s, whereas 18 F‐ FDG PET is potentially useful in identifying aggressive NET s with poorer outcomes. More studies are needed to better define the role of different radiotracer‐based PET imaging in patients with MEN syndromes.